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The aim of this preliminary study was to evaluate the eﬀect of low-dose oral vitamin D in combination with current disease-
modifying therapy on the prevention of progression of relapsing-remitting multiple sclerosis (RRMS). A phase II double-blind
placebo-controlled randomized clinical trial conducted between October 2007 and October 2008 included 50 patients with
conﬁrmedRRMSaged25to57yearsandnormalserum25-hydroxyvitaminD.Theywererandomlyallocatedtoreceive12months
oftreatmentwitheitherescalatingcalcitriol dosesupto0.5µg/dayorplacebocombinedwithdisease-modifyingtherapy.Response
to treatment was assessed at eight-week intervals. In both groups, the mean relapse rate decreased signiﬁcantly (P<0.001). In the
25 patients treated with placebo, the mean (SD) Expanded Disability Status Scale (EDSS) increased from 1.70 (1.21) at baseline to
1.94 (1.41) at the end of study period (P<0.01). Average EDSS and relapse rate at the end of trial did not diﬀer between groups.
Adding low-dose vitamin D to routine disease-modifying therapy had no signiﬁcant eﬀect on the EDSS score or relapse rate. A
larger phase III multicenter study of vitamin D in RRMS is warranted to more assess the eﬃcacy of this intervention.
1.Introduction
Multiple sclerosis (MS) is an inﬂammatory, demyelinat-
ing, immune-mediated, and debilitating disease that aﬀects
young adults and is often associated with signiﬁcant disabil-
ity and impaired quality of life [1, 2]. Disability and high
morbidity are common features of the disease [3]; symptom
management must therefore be a long-term consideration,
as disease-modifying therapies only slow the progression of
thedisease[4].Despiteextensiveresearchtodevelopeﬀective
pharmacological treatments to alleviate exacerbation and
chronic neurological damage in MS, current available drugs
have limited eﬃcacy and considerable adverse eﬀects [5–7].
Vitamin D is a lipid-soluble vitamin synthesized by con-
version of 7-dehydrocholesterol to vitamin D in the skin.
Vitamin D is a secosteroid hormone known to play an
important role in bone formation and mineral homeostatis.
Recent studies have also suggested that vitamin D aﬀects
immune and central nervous system (CNS) development
and function and has strong immune-regulatory capacity
[8–11]. Some in vitro and animal studies suggest that
vitamin D supplementation reduced inﬂammatory inﬁltra-
tion in the CNS by suppressing function of antigen-pre-
senting cells [12]. Mice treated with dietary 1, 25-dihydrox-
yvitamin D3 prior to induction of experimental autoim-
mune encephalomyelitis (EAE), an animal model for MS,
did not develop symptoms of EAE, compared with 100%
incidence in the control group [12]. In mice with EAE,
1, 25-dihydroxyvitamin D3 injections followed by dietary
supplementation halted disease progression. The eﬀects of
vitamin D were reversible, as evidenced by EAE progression2 Multiple Sclerosis International
after discontinuation of the supplement. Epidemiological
evidence from observational studies also has suggested that
vitamin D may help prevent MS, reduce exacerbations, and
may be useful addition to standard MS therapy [13]. These
ﬁndings suggest that the active form of vitamin D may be
eﬀective in treating patients with MS.
Whether vitamin D is eﬀective in human MS is not
known. There are, however, few small open-label or noncon-
trolled clinical trials relating vitamin D to MS progression
[14–18]. We therefore examined the therapeutic eﬀect of
low-dose vitamin D on the prevention of progression of MS.
Because vitamin D is able to eﬀectively suppress acute EAE,
whichhasmanysimilarities toMS[11,12],has low or absent
toxicity, and has been safely used in humans orally; even
modest therapeutic eﬀectiveness of this drug would be useful
in the treatment of MS.
InthepresentexploratoryphaseIItrial,wecomparedthe
eﬀects of low-dose vitamin D and a placebo in combination
with current disease-modifying therapy in terms of their
safety, tolerability, and relative eﬃcacy in preventing the pro-
gression of relapsing-remitting multiple sclerosis (RRMS).
2. Patientsand Methods
2.1. Patients. A total of 50 consecutive patients with RRMS
were recruited from neurology outpatient clinics of Isfahan
University of Medical Sciences and the Isfahan Multiple
Sclerosis Society between October 2007 and October 2008,
with the last patient completing the 12 month trial in
March 2009. All of the cases had a magnetic-resonance-
imaging- (MRI-) supported diagnosis. Entry criteria were
either sex, age between 15 and 60 years with a MRI, clinical
or laboratory-supported diagnosis of deﬁnite RRMS [19]
mean (standard deviation (SD)) duration 4.3 (2.2) years,
range 1–12 years, stable neurological functioning for at
least one month prior to study entry, and an EDSS [19]
score ≤6, serum 25-hydroxyvitamin D level >40ng/mL
[20] and a willingness to continue current medications
for the duration of the study. Assessments of serum 25-
hydroxyvitamin D level were carried out routinely as part of
the clinical management of MS and used to detect vitamin
D insuﬃciency. Exclusion criteria were evidence of sub-
stantial abnormalities in neurological, psychiatric, cardiac,
endocrinological, hematologic, hepatic, renal, or metabolic
functions, use of digitalis, vitamin D supplement, any con-
dition predisposing to hypercalcemia, nephrolithiasis, renal
insuﬃciency and pregnancy as determined by history, phys-
ical examination, and screening blood tests. Patients with
secondary-progressive and primary-progressive MS were
excluded to ensure that the treatment group was homoge-
neous in terms of course of disease and possibly also in
disease mechanisms. Tenets of the current version of the
Declaration of Helsinki were followed, institutional ethical
committee approval was granted, and the nature of the trial
was explained to the participants. After a detailed discussion
with the neurologist, patients made a ﬁnal decision, and each
participant provided written informed consent. This trial
was registered with Iranian Registry of Clinical Trials (ID
IRCT201104166202N1).
2.2. Randomization Scheme. A total of 65 patients were eli-
gible for study. Fifteen patients were excluded because their
type of MS was not RRMS, they refused entry, or they did
not meet the inclusion criteria. Fifty patients (6 (12.0%)
men, 44 (88.0%) women) completed the study without in-
terruption and were assigned randomly to one of the two
self-administer treatment groups. Patients were randomized
according to a preexisting list produced by a computer pro-
gram. All patients continued on their own RRMS treatment
regimen. The ﬁrst treatment group received 0.25µga d j u n c t
calcitriol (a metabolically active form of vitamin D (1, 25-
dehdroxyvitamin D3) (trade name Zavitrol, Zahravi Pharm.
Co. Tabriz, Iran) per day and increased to 0.5µg/day after
2 weeks and continued for 12 months. The second group
received placebo for 12 months. Both were administered
as capsules twice a day orally before meals. Patients were
allowed access to their routine RRMS treatments. Compli-
ance with the study treatment was veriﬁed by asking the
patients about missed doses and by counting unused sachets.
In the month preceding the trial, all patients underwent
pretreatment evaluation to record demographic data, com-
plete neurologic and medical history, the ﬁnding of physical
and neurologic examination, and previous treatment. Figure
1 illustrates the patient allocation algorithm. In the ﬁnal
sample of participants mean (SD) age was 38.2 (8.4) years
(range from 25 to 57 years) and baseline EDSS score ranged
f r o m1 . 0t o5 . 5 .
2.3. Patient Evaluation. The trial was double-blinded in that
both patient and physician who assessed the outcome were
unaware of the type of treatment each patient received.
Masking of the active and placebo treatments was preserved
by creating treatments that looked identical. The hospital
pharmacist was informed of all randomization assignments
and was responsible for labeling the study drug and main-
taining a master list linking participants and their treatment
assignments. Participants were evaluated by a qualiﬁed
neurologist at baseline, 2, 4, 6, 8, 10, and 12 months after
the start of the therapy to evaluate the development of side
eﬀects of the medications, compliance, and disease activity
(EDSS and evaluation of relapse occurrence). Brain MRI
with gadolinium was carried out at baseline and 12 months.
All patients were evaluated by the same physician (HD), who
did not know which patients had received which treatment.
The number of relapses, the proportion of patients free
from relapses, the EDSS, and other medical events were
recorded at each visit. Acute relapse was deﬁned as the ap-
pearance of a new neurological symptom or severe dete-
rioration in a preexisting symptom that lasted for at least
24h in the absence of fever/infection and caused an increase
of at least 1 point in EDSS [21]. The primary outcome
measure was deterioration from baseline to 12 months after
receiving vitamin D or placebo as measured by the EDSS.
Mean changes in relapse rate were also calculated for both
groups.
2.4. Statistical Analysis. The study was powered (80%) to
detect (with a two-sided alpha of 0.05) a mean diﬀerence in
EDSS score from baseline of 0 point. Statistical analysis wasMultiple Sclerosis International 3
Assessed for eligibility (n = 65)
Excluded (n = 15)
Secondary progressive (n = 7)
Primary progressive (n = 2)
Other reasons (n = 6)
Randomized (n = 50)
Vitamin D (n = 25) Placebo (n = 25)
Completed (n = 25) Completed (n = 25)
Enrollment
Figure 1: Design of the trial to compare oral vitamin D (0.5µg/day) versus placebo in patients with relapsing-remitting multiple sclerosis.
based on the intention-to-treat principle. The results for the
groups that received vitamin D or placebo were compared
with Student’s t-test for independent samples and analysis
of variance with repeated measures over time; the results
at baseline and after 12-months within each group were
compared with paired Student’s t-tests. We used the chi-
square or Fisher’s exact test to compare proportions. The
results are expressed as the mean (SD), and P<0.05 was
considered statistically signiﬁcant. All statistical tests were
two-sided. Analyses were done using SPSS for Windows
(SPSS Inc., Chicago, IL, USA). There was no interim analysis
of treatment eﬀects.
3. Results
Fifty patients who met the entry criteria were enrolled in
the study. Patient compliance with treatment was good.
All 50 patients who completed treatment were available
for followup at 12 months. The two treatment groups
were generally well matched at baseline with regard to
age, gender, duration of RRMS, EDSS, number of relapse-
free years prior to the trial, and other MS characteristics.
Most participants (86.0%) had received interferon beta,
statins (10.0%), or immunosuppressive drugs (4.0%) with
no signiﬁcant diﬀerences between groups. Mean (SD) age
in the vitamin D and placebo groups was 38.6 (8.4) and
37.9 (7.9) years, respectively. Mean (SD) EDSS at the start
of treatment was 1.6 (0.7) in the vitamin D group and 1.7
(1.2) in the placebo group (Table 1). Two patients had two
attacks during the preceding year,and the reminders hadone
attack.
Vitamin D treatment was tolerated well and most of
t h ea d v e r s ee v e n t sr e p o r t e dw e r em i l di ns e v e r i t y .T h em o s t
common side eﬀects of vitamin D were constipation (n =
6), dyspepsia (n = 6), fatigue (n = 4), and headache
(n = 2). The most common side eﬀects of placebo were also
constipation (n = 4), dyspepsia (n = 2), fatigue (n = 5),
and headache (n = 1). There were no substantial diﬀerences
between vitamin D and placebo groups in frequency or
pattern of events. There were no instances of urinary
dysfunction or symptomatic nephrolithiasis.
Changes in mean EDSS and number of relapses before
and after receiving vitamin D or placebo are shown in Table
2. In placebo groups, the average EDSS score increased
signiﬁcantly. The average increase from baseline was 0.24
point (95% CI, 0.08–0.40). In patients treated with vitamin
D, mean EDSS score did not change. In both groups, the
mean relapse rate decreased signiﬁcantly. Of the 25 patients
treated with vitamin D, the mean (SD) relapse rate decreased
from 1.04 (0.20) at baseline to 0.32 (0.48) at the end of
study period (P<0.001). In the 25 patients treated with
placebo, the mean (SD) relapse rate decreased from 1.04
(0.20) at baseline to 0.40 (0.58) at the end of study period
(P<0.001). After 12-months, 17 (34.0%) relapses had
occurred; 8 (32.0%) in the vitamin D and 9 (36.0%) in the
placebo group. After 12 months, 33 of 50 patients (66.0%)
remained relapse-free; 17 (68.0%) in the vitamin D and 16
(64.0%) in the placebo group. The odds ratio was 1.06 (95%
CI, 0.71–1.58), indicating there is no evidence of an eﬀect on
theoddsofremainingrelapse-freeduringtheﬁrst12months
of therapy in patients who received vitamin D compared to
those who received the placebo.
The overall cross-tab analysis revealed no signiﬁcance
diﬀerences in the EDSS or number of relapses at the end of
the study period between the vitamin D and placebo groups
(Table 3).
The overall analysis of repeated measures ANOVA re-
vealed no signiﬁcance diﬀerences in the EDSS at the end
of trial between vitamin D and placebo groups (P>0.05)
(Table 4). Figure 2 shows the estimated mean changes in
EDSS score after 2, 4, 6, 8, 10, 12 months of followup in
two groups. Those receiving vitamin D showed no changes
but those receiving placebo showed progressive neurologic
deterioration.4 Multiple Sclerosis International
Table 1: Characteristics of patients with relapsing-remitting multiple sclerosis who received low-dose vitamin D (0.5µg/day) or placebo at
baseline.
Characteristics
Treatment group at baseline
Diﬀerences (95% CI) Vitamin D (n = 25)
Mean (SD)
Placebo (n = 25)
Mean (SD)
Age (years) 38.6 (8.4) 37.9 (7.9) 0.7 (−3.9, 5.3)
Duration of multiple sclerosis (years) 4.5 (2.7) 4.1 (1.7) 0.4 (−0.9, 1.7)
EDSS at baseline 1.6 (0.7) 1.7 (1.2) −0.1 (−0.7, 0.5)
Relapses in previous year 1.04 (0.2) 1.04 (0.2) 0.0 (−0.1, 0.1)
No. (%) No. (%)
Gender
Men 3 (12.0) 3 (12.0) 0.0 (−18.0, 18.0)
Women 22 (88.0) 22 (88.0) —
Concomitant medications
Interferon beta 22 (88.0) 21 (84.0) 4.0 (−15.2, 23.2)
Statin 2 (8.0) 3 (12.0) −4.0 (−20.6, 12.6)
Immunosuppressive drug 1 (4.0) 1 (4.0) 0.2 (−10.9, 10.9)
EDSS at baseline
≤1.5 15 (60.0) 18 (72.0) −12.0 (−38.0, 14.0)
2.0–2.5 8 (32.0) 4 (16.0) 16.0 (−7.3, 39.3)
≥3.0 2 (8.0) 3 (12.0) −4.0 (−20.6, 12.6)
Relapses in previous year
1 24 (96.0) 24 (96.0) 0.0 (−10.9, 10.9)
2 1 (4.0) 1 (4.0) 0.0 (−10.9, 10.9)
CI: conﬁdence interval, EDSS: expanded disability status scale.
Table 2: Comparison of Expanded Disability Status Scale (EDSS) and relapses in 50 patients with relapsing-remitting multiple sclerosis
before and 12 months after treatment with low-dose vitamin D and placebo.
Treatment group Number Baseline
Mean (SD)
12 months after therapy
Mean (SD)
Diﬀerences (95% CI)
EDSS
Vitamin D 25 1.63 (0.73) 1.63 (0.70) 0.0 (−0.15, 0.15)
Placebo 25 1.70 (1.21) 1.94 (1.41) −0.24 (−0.40, −0.08)∗
Relapses
Vitamin D 25 1.04 (0.20) 0.32 (0.48) 0.72 (0.50, 0.94)∗∗
Placebo 25 1.04 (0.20) 0.40 (0.58) 0.64 (0.38, 0.90)∗∗
∗P<0.01, ∗∗P<0.001, CI: conﬁdence interval.
4. Discussion
In this exploratory phase II study we found no signiﬁcant
difference in relapse rate or change in EDSS between par-
ticipants who took the placebo versus those who received
adjunct low-dose oral vitamin D during 12 months. No
unusual or unexpected safety risks were found with vita-
min D therapy in our study population with RRMS. The
spectrum of most frequent adverse events is similar to that
in previous studies of vitamin D treatment for MS, with
gastrointestinal side eﬀects being most common. Previous
studies have shown that vitamin D is fairly safe [14],
especially in terms of its eﬀects on the gastrointestinal tract
[14]. We did not ﬁnd any signiﬁcant diﬀerences between
the active drug and the placebo in safety, and there were no
distinct patterns in adverse events.
The eﬃcacy of vitamin D for treatment of MS has been
examined in noncontrolled trials with variable results. The
eﬀect of calcium, magnesium, and vitamin D supplemen-
tation on relapse rate was evaluated in 16 young patients
with MS [15]. Participants received magnesium 10mg/kg,
calcium 16mg/kg, and cod liver oil 20g supplying 5000IU
of vitamin D per day. The primary endpoint of the trial
was the actual number of exacerbations compared with the
expected number. There was a signiﬁcant reduction in the
actual number of exacerbations compared with the expected
number. The authors concluded that calcium, magnesium,
and vitamin D supplementation reduced the number ofMultiple Sclerosis International 5
Table 3: Comparison of Expanded Disability Status Scale (EDSS) and relapses in 50 patients with relapsing-remitting multiple sclerosis after
12 months of treatment with low-dose vitamin D and placebo.
Treatment group
Diﬀerences (95% CI)
Vitamin D (n = 25)
Mean (SD)
Placebo (n = 25)
Mean (SD)
EDSS at 12-months 1.63 (0.70) 1.94 (1.41) −0.31 (−0.94, 0.32)
Relapses at 12-months 0.32 (0.48) 0.40 (0.58) −0.08 (−0.38, 0.22)
Table 4: Comparison of Expanded Disability Status Scale (EDSS) and relapses in 50 patients with relapsing-remitting multiple sclerosis
before and 2, 4, 6, 8, 10, 12 months after treatment with low-dose vitamin D and placebo.
Characteristics
Treatment group
Diﬀerences (95% CI)
Vitamin D (n = 25)
Mean (SD)
Placebo (n = 25)
Mean (SD)
EDSS
At baseline 1.60 (0.72) 1.70 (1.22) −0.10 (−0.67, 0.47)
After 2 months 1.56 (0.70) 1.70 (1.22) −0.14 (−0.71, 0.43)
After 4 months 1.56 (0.70) 1.74 (1.23) −0.18 (−0.75, 0.39)
After 6 months 1.60 (0.70) 1.84 (1.32) −0.24 (−0.84, 0.36)
After 8 months 1.54 (0.66) 1.90 (1.42) −0.36 (−0.99, 0.27)
After 10 months 1.63 (0.70) 1.94 (1.41) −0.31 (−0.94, 0.32)
After 12 months 1.63 (0.70) 1.94 (1.41) −0.31 (−0.94, 0.32)
Diﬀerence at 12-months and baseline 0.03 (0.36) 0.24 (0.39) −0.21 (−0.45, −0.3)∗
Relapses
At baseline 1.04 (0.20) 1.04 (0.20) 0.00 (−0.11, 0.11)
After 12 months 0.32 (0.48) 0.40 (0.58) −0.08 (−0.38, 0.22)
Diﬀerence at 12-months and baseline −0.72 (0.54) −0.64 (0.64) −0.08 (−0.42, 0.26)
∗P<0.05. CI: conﬁdence interval.
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Figure 2: Estimated mean changes in Expanded Disability Status
Scale after 2, 4, 6, 8, 10, 12 months of followup.
exacerbations experienced by patients with MS. Vitamin
D was coadministered with calcium and magnesium, pre-
venting its actual eﬀectiveness. In addition, the source of
vitamin D used in this study, cod liver oil, also contains
fatty acids, which may have contributed to the positive
results. An open-label study evaluated 1, 25-hydroxyvitamin
D3 (calcitriol) treatment in 15 patients with RRMS [16].
Oral calcitriol was started at 0.5µg daily and increased by
0.5µg/day every 2 weeks until the target dosage of 2.5µg/day
was reached. The authors suggested that calcitriol therapy
was unlikely to aggravate symptoms of MS. Another open-
labeltrialofalfacalcidol(activatedvitaminD)wasconducted
in 5 patients with MS [17]. The patients had RRMS, with
a relatively low exacerbation rate and received alfacalcidol
1.5µg/day for 6 months. Three patients remained stable, 1
had improvement in neurologic status, and 1 developed an
acute relapse. No adverse eﬀects were reported with use of
alfacalcidol. Another pilot study enrolled 11 patients with
RRMS to determine the safety and eﬃcacy of 19-nor-1,
25-dihydroxyvitamin D2, a vitamin D analog [18]. Patients
received 6 monthly MRI scans prior to starting treatment.
After 19-nor-1, 25-dihydroxyvitamin D2 was titrated to the
maximally tolerated dose (average 4µg), participants re-
ceived an additional 6 monthly MRI scans. While no adverse
eﬀects were reported, no signiﬁcant changes were seen in
clinical symptoms or MRI lesions.
In summary, these four studies involved a total of 47
patients,varyingingender,age,dose,typeofvitaminDused,
type of MS, and follow-up time. Interpretation of data is6 Multiple Sclerosis International
complicated by the demographic variability in the patients,
by the methodological problems related to the outcome
measures in these trials, and by their subsequent analyses.
In addition, statistical analyses did not always deal with the
small number of patients and the small eﬀect sizes.
The eﬃcacy of vitamin D for treatment of MS has been
examined in an open-label randomized controlled trial
conducted over 52 weeks, which treated 25 patients with
escalating doses of vitamin D compared with control [14].
The trail provided some evidence of the potential beneﬁt
of the intervention on several outcomes, that is, the annu-
alized relapse rate, EDSS score, and suppression of T-cell
proliferation and illustrated a measure of comparative safety
in the relative absence of any adverse events or of high
serum calcium level over the study period. Recently, the
eﬀect of high-dose vitamin D2 (6000IU/day) compared with
low-dose (1000IU/day) supplementation was evaluated in
23 patients with RRMS [22]. The primary endpoint of the
trial was cumulative number of new gadolinium-enhancing
lesions and change in total volume of T2 lesions. Secondary
endpoints were EDSS and relapse rate. They did not ﬁnd
therapeutic advantages in RRMS for high-dose vitamin D2
compared with low-dose vitamin D2 supplementation. The
high-dose group actually had signiﬁcantly more relapses and
worse disability than the low-dose group at the end of the
study. Thus in this study, there seemed to be no advantage
from high-dose vitamin D supplementation in patients with
MS compared to supplementation for adequate vitamin D
levels. These studies were too small to make a deﬁnitive
conclusion about the vitamin’s eﬃcacy. To the best of our
knowledge, no other studies are available comparing low-
dose vitamin D with placebo, and this is the ﬁrst randomized
clinical trial to compare the eﬀect of adjunct low-dose
vitamin D in combination with current disease-modifying
therapy in preventing the progression of RRMS.
The precise mechanism of action of vitamin D in RRMS
has not been fully elucidated yet. Multiple sclerosis has been
identiﬁed as Th1-mediated autoimmune diseases [23], but it
is Th2-mediated responses which have beneﬁcial eﬀects on
the severity and progression of the disease [24, 25]. Response
mediated by Th2 represents one of the major mechanisms
underlyingAg-speciﬁcimmunetoleranceinduction[26–29].
Vitamin D has anti-inﬂammatory action in vitro, including
enhanced Th2 and decreased Th1 cytokine production, den-
dritic cell eﬀects, and enhanced macrophage phagocytosis
[30, 31]. Vitamin D has been shown to eﬀectively suppress
T cell and antigen-presenting cell activation [30, 31]. It is
also known to reduce inﬂammatory inﬁltration into the CNS
in animal model [12]. More importantly, it has been shown
to be safe for use in human [14, 16]. Ex vivo and in vitro
studies showed that vitamin D induced blockade of Th1
and upregulation of Th2 response [12]. These results suggest
vitamin D is able to induce the Th2 response and inhibit
acute autoimmune attack on the CNS.
Albeit, this study is one of the largest placebo-controlled
trials to date of eﬀect of oral vitamin D in combination
with current disease-modifying therapy on the prevention
of progression of RRMS; the strongest limitation of it is the
small number of patients included, and it seems unlikely that
small eﬀect can be ruled out. The eﬃcacy should therefore
be tested in a larger sample. The present results clearly need
to be replicated and extended across multiple centers and
investigators. The possible explanation for the discrepancies
between these results and those of previous studies might be
related to some methodological diﬀerences, such as patient
selection, the examination of patients at diﬀerent stages in
the natural history of MS, and vitamin D type and dosage.
We used 0.5 µgcalcitriolperdayfor12-months,whileBurton
et al. [14] used up to 40,000IU/day vitamin D for over 28
weeks, Wingerchuk et al. [16] used oral calcitriol 2.5µg/day
for 48 weeks, Goldberg et al. [15]u s e du pt o5 , 0 0 0 I Uo f
vitamin D per day for one to two years, and Achiron et al.
[17] used alfacalcidol 1.5µg/day for 6 months. Although
substantial evidence supports the safety of even large dose
of vitamin D, such evidence is based on studies of limited
size and duration. The best level of vitamin D for health is
uncertain. Many experts believe that blood levels of vitamin
Da b o v e3 0 n g / m La r ea d e q u a t e[ 32]. Most found that
patients with MS appeared to beneﬁt from having adequate
vitamin D levels compared to insuﬃciency or deﬁciency. A
few studies also suggested that levels higher than 30ng/mL
may further help protect patients with MS [32]. Therefore,
our study suggests that the dose of 0.5µg/day vitamin D
in patients with suﬃcient serum 25-hydroxyvitamin D level
may be considered relatively safe.
In conclusion, this exploratory phase II comparative trial
of low-dose vitamin D supplementation and placebo showed
that adding vitamin D to routine disease-modifying therapy
had no signiﬁcant eﬀect on the EDSS score or relapse rate.
Further studies with larger sample and longer followup are
needed.
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